Date: July 6, 2006

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum	Bin Blun	
Name (Print)	Signature	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	DOI et al.	Examiner:	Unassigned
Application No.:	10/562,942	Group Art Unit:	Unassigned
Filed:	December 29, 2005)	Confirmation No.:	Unassigned
Docket No.:	3190-088	Customer No.:	33432

For: INF

INHIBITION OF NERVE CELL DEATH BY INHIBITING DEGRADATION OF SHC3, ATF6 or CREBL1 by HTRA2 and Method of Ameliorating

NEURODEGENERATIVE DISEASES

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>PURSUANT TO 37 CFR 1.97(b)</u>

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

July 6, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the threemonth period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Information Disclosure statement, then applicants respectfully petition under 37 C.F.R.§ 1.97(c) to consider the documents set forth in the Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Information Disclosure Statement U.S. Patent Application No. 10/562,942

Respectfully submitted,

Luke A. Kilyk Reg. No. 33,251

Atty. Docket No.: 3190-088 KILYK & BOWERSOX, P.L.L.C. 400 Holiday Court, Suite 102

Warrenton, VA 20186 Tel: (540) 428-1701 Fax: (540) 428-1720

Enclosures: PTO/SB/08 w/13 Documents

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

		Complete if Known			
Substitut	e for form 1449A/	РТО		Application Number	10/562,942
INI	FORMATION	DISCLO	CLIDE	Filing Date	December 29, 2005
				First Named Inventor	DOI et al.
	TATEMENT B			Art Unit	Unassigned
(use as many sheets as necessary)			ssary)	Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	3190-088

				U.S. PAT	ENT DO	CUMENTS			
		Document Number	Publication	Date		Name of Pa	tentee or	Pages, Columns, I	Lines, Where
Examiner Initials*	Cite No. ¹	Number - Kind Code ² (if known)	MM-DD-Y	vvv '''		Applicant of Cite		Relevant Passages or Relevant Figures Appear	
		US-							
	1	US-		***************************************	***************************************				
		US-		1	***************************************				
		US-			***************************************				
		US-							***************************************
		US-					——————————————————————————————————————		***************************************
		US-							
		US-							
	l	US-							
		US-							
	<u> </u>	US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-					······································	***************************************	
		US-							
		US-							
		US-					······································		***************************************
			FO	REIGN P	ATENT	DOCUMEN	TS		···
		Foreign Patent Docume	Publication Date Name of Patentee or Applicant			Pages, Columns, Lines,			
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)		MM-DD-		Cit	ed Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 03/027145 A1		04-03-0	3	Takahash	i et al.		English Translation
				·					

							**************************************	-	

Examine Signatur							Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Comple	te if Known
Substitu	te for form 1449A/	РТО		Application Number	10/562,942
INI	EODMATION.	DISCLO	CLIDE	Filing Date	December 29, 2005
	Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2	First Named Inventor	DOI et al.		
_			Art Unit	Unassigned	
(use as many sneets as necessary)		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	3190-088

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.	T²
		YAMAGUCHI et al., "Bax Plays a Pivotable Role in Thapsigargin-induced Apoptosis of Human Colon	
		Cancer HCT116 Cells by Controlling Smac/Diablo and Omi/HtrA2 Release form Mitochondria", Cancer	
		Research, Vol. 63, April 1, 2003, pp. 1483-1489. CONTI et al., "Shc Signaling in Differentiating Neural Progenitor Cells", Nature Neuroscience, Vol. 4, No.	
		6, June 2001, pp. 579-586.	
	· 	HAZE et al., "Identification of the G13 (cAMP-response-element-binding Protein-related Protein) Gene	
		Product Related to Activating Transcription Factor 6 as a Transcriptional Activator of the Mammalian Unfolded Protein Response", Biochem. Journal, Vol. 355, 2001, pp. 19-28.	
		KAUFMAN, "Orchestrating the Unfolded Protein Response in Health and Disease", The Journal of Clinical Investigation, Vol. 110, No. 10, November 2002, pp. 1389-1398.	
		SUZUKI et al., "A Serine Protease, HtrA2, is Released from the Mitochondria and Interacts with XIAP, Inducing Cell Death", Molecular Cell, Vol. 8, September 2001, pp. 613-621.	
		HEGDE et al., "Identification of Omi-HtrA2 as a Mitochondrial Apoptotic Serine Protease that Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction", The Journal of Biological Chemistry, Vol. 277, No. 1, 2002, pp. 432-438.	
		MARTINS et al., "The Serine Protease Omi-HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif", The Journal of Biological Chemistry, Vol. 277, No. 1, 2002, pp. 439-444.	
		"A Variety of Functions of a Shc Family, an Adapter Molecule Working in Phosphotyrosine-Mediated Signalings, and Progress of it's Study in Nerve System", Seikagaku, Vol. 73, No. 11, 2001, pp. 1322-1325.	English Translation
		KUDO, "ER Stress and Neurodegenerative Disease", Japan Journal of Neuropsychopharmacology, Vol. 23, No. 3, 2003, pp. 105-108.	English Translation
		SUZUKI et al., "A Novel Mitochondrial Cell Death-Inducing Factor: HtrA2/Omi", Jikken Igaku, Vol. 20, No. 1, 2002, pp. 73-75.	English Translation
		KOUGAKU, Saibou, Cell Technology, 2002, Vol., 21, No. 4, pp. 360-394.	English Translation
		International Preliminary Report on Patentability for PCT/JP2004/014378, mailed April 13, 2006.	
Examine:	r	Date Capalidated	
Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.